Therapeutic Gene Editing. A Lot Done, a Lot More...
CMN Interview
Feb. 5, 2024
Clinical-Grade gRNA for Genomic Medicines: Making Sense of the CRISPR Regulatory Landscape | Monday June 12, 2023 | 3:00 pm–4:00 pm CEST / 9:00 am–10:00 am EDT
On-demand webinar is available - Follow this link
Clinical-Grade gRNA for Genomic Medicines: Making Sense of the CRISPR Regulatory Landscape
In this webinar, Synthego's Senior Director of Quality & Regulatory, Beckinam Nowatzke, and Senior Regulatory Specialist Lina Jamis will elaborate on Synthego’s preclinical offerings in support of CRISPR therapy developers and an interpretation of FDA’s expectations for CRISPR gene editing components.
What will you learn:
- Health authority expectations for sgRNA as a gene editing component for CRISPR clinical applications
- Synthego’s Regulatory Affairs framework for supporting CRISPR therapy developers
- Discern CRISPR standards through Synthego's Regulatory Intelligence
Webinar Programme:
- 15.00 Welcome and introduction by CRISPR Medicine News
- 15.05 Beckinam Nowatzke and Lina Jamis |Clinical-Grade gRNA for Genomic Medicines: Making Sense of the CRISPR Regulatory Landscape
- 15.45 Q & A with Beckinam Nowatzke and Lina Jamis
- 16.00 Close by CRISPR Medicine News
Speakers: Beckinam Nowatzke, Senior Director of Quality & Regulatory, Lina Jamis, Senior Regulatory Specialist, Synthego Corporation, Redwood City, CA
Title: Clinical-Grade gRNA for Genomic Medicines: Making Sense of the CRISPR Regulatory Landscape
Speakers
Beckinam Nowatzke, Senior Director of Quality & Regulatory, Lina Jamis, Senior Regulatory Specialist
Becki and Lina have a combined 30+ years of experience in the Regulatory Affairs space, with particular focus on regulatory trends and chemistry, manufacturing, and control for cell and gene therapeutics.
CMN Articles - Regulations
